INO INOVIO PHARMACEUTICALS, INC.

Nasdaq inovio.com


$ 2.39 $ -0.11 (-4.47 %)    

Friday, 17-Oct-2025 19:50:41 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 2.35
$ 2.42
$ 2.35 x 200
$ 2.51 x 7
$ 2.35 - $ 2.44
$ 1.30 - $ 5.83
709,589
na
124.89M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-06-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-09-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-12-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-14-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-15-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 inovio-on-track-to-complete-ino-3107-biologics-license-application-by-2h25-targets-fda-acceptance-by-year-end

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U....

 hc-wainwright--co-reiterates-neutral-on-inovio-pharmaceuticals-maintains-3-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintai...

 inovio-pharmaceuticals-q2-eps-061-beats-062-estimate

Inovio Pharmaceuticals (NASDAQ:INO) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of...

 inovios-announces-peer-reviewed-data-from-a-retrospective-study-investigating-the-long-term-clinical-and-safety-response-of-patients-treated-with-ino-3107-were-published-online-in-the-laryngoscope-ino-3107-shows-sustained-improvement-in-rrp-patients-cutting-surgeries-by-over-75-in-year-2

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compar...

 piper-sandler-initiates-coverage-on-inovio-pharmaceuticals-with-overweight-rating-announces-price-target-of-5

Piper Sandler initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight rating and announces Price Target o...

 avacta-appoints-dr-david-liebowitz-as-chief-medical-officer-to-lead-cancer-drug-strategy

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appoi...

Core News & Articles

https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-rega...

 rbc-capital-reiterates-sector-perform-on-inovio-pharmaceuticals-maintains-5-price-target

RBC Capital analyst Gregory Renza reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Sector Perform and maintains $5 pric...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION